Results 31 to 40 of about 104,562 (257)

One Rare Warfarin Resistance Case and Possible Mechanism Exploration

Pharmacogenomics and Personalized Medicine, 2023
Li Zhao,1 Zhenguo Zhai,2 Pengmei Li1 1Pharmacy Department, China-Japan Friendship Hospital, Beijing, People’s Republic of China; 2Department of Respiratory and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, People’s Republic of ...
Zhao L, Zhai Z, Li P
doaj  

Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range

, 2019
Introduction: Warfarin is an oral anticoagulant that requires ongoing monitoring with time in therapeutic range (TTR), a common measure of the quality of warfarin control and likelihood of adverse events including bleeds.
Bertram, Victoria, Yeo, Kelly, Anoopkumar-Dukie, Shailendra, Bernaitis, Nijole   +3 more
core   +1 more source

Utility of TTR-INR guided warfarin adjustment protocol to improve time in therapeutic range in patients with atrial fibrillation receiving warfarin

Scientific Reports
Warfarin remains the most prescribed oral anticoagulant of choice in atrial fibrillation (AF) patient in resource-limited settings. Despite evidence linking Time in Therapeutic Range (TTR) to patient outcomes, its use in clinical practice is not ...
Paisit Kosum, Noppachai Siranart, Kunathip Nissaipan, Wattakorn Laohapiboolrattana, Walit Sowalertrat, Kanittha Triamamornwooth, Rawiwan Arunphan, Apiradee Sriyom, Voravut Rungpradubvong   +8 more
doaj   +1 more source

Warfarin time in therapeutic range of primary healthcare patients in the Western Cape Province, South Africa

British Journal of Clinical Pharmacology, EarlyView.
Introduction Warfarin therapy is the mainstay of anticoagulation treatment in South Africa and requires frequent INR monitoring due to interindividual patient variability. Time in therapeutic range (TTR) reflects the proportion of total treatment time during which INR values are within therapeutic range.
Masudah Paleker, Christopher Kelly, Robin Dyers, Eric Decloedt   +3 more
wiley   +1 more source

Awareness of subconjunctival bleeding on warfarin therapy patient [PDF]

, 2010
A case of subconjunctival bleeding as an initial sign of progressive bleeding caused by warfarin therapy on patient with mitralregurgitation, its clinical signs, multidisciplinary approach and management.
Diana Haryati Kusumastuti, -, Dewi Rosalina, -, Ratna Doemilah, -, Evelyn Komaratih, -   +3 more
core   +1 more source

Clinical relevance of pharmacogenomic information for improving prescribing practices in acutely admitted older medical patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Safe prescribing and effective medication review during acute hospitalization depends on accurate information about liver and kidney function because these organs are responsible for the elimination of most medications. While estimates for kidney function are widely used, comparable markers of hepatic drug‐metabolizing capacity are not routinely ...
Louise Westberg Strejby Christensen, Anne Kirstine Boas, Emilie Clausen, Nicoline Elers Koch, Anne Byriel Walls, Lotte Stig Nørgaard, Michael Asger Andersen, Anissa Aharaz, Rikke Lundsgaard Nielsen, Olivia Bornæs, Juliette Tavenier, Baker Nawfal Jawad, Helle Gybel Juul‐Larsen, Esben Iversen, Ove Andersen, Lona Louring Christrup, Kim Peder Dalhoff, Morten Baltzer Houlind   +17 more
wiley   +1 more source

Acute Abdomen Due to Uncontrolled Use of Warfarin: Spontaneous Intra-abdominal

, 2017
Warfarin is an oral anticoagulant, which is commonly used in the treatment and prophylaxis of thromboembolic conditions. Bleeding is the primary adverse effect associated with warfarin.
Hasan Ökmen, Önder Akkuş, Fatih Dal, Serkan Sarı, Turgay Erginel, Meltem Küçük Yılmaz   +5 more
core   +1 more source

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

Patterns of warfarin use in subgroups of patients with atrial fibrillation: a cross-sectional analysis of 430 general practices in the United Kingdom.

PLoS ONE, 2013
BackgroundDespite the proven efficacy of warfarin, its use in patients with Atrial Fibrillation (AF) is reportedly low. We investigated the underuse and overuse of warfarin in the management of AF in general practices in the United Kingdom (UK) against ...
Mohammed A Mohammed, Tom Marshall, Krishnarajah Nirantharakumar, Andrew Stevens, David Fitzmaurice   +4 more
doaj   +1 more source

Warfarin Sodium Stability in Oral Formulations

Molecules, 2021
Warfarin sodium is a low-dose pharmaceutical blood thinner that exists in two forms: the clathrate form and the amorphous form. In commercially available warfarin sodium oral suspension, the active pharmaceutical ingredient (API) is added in the ...
Evangelia Dimitrokalli, Stefani Fertaki, Michail Lykouras, Petros Kokkinos, Malvina Orkoula, Christos Kontoyannis   +5 more
doaj   +1 more source